Earnings ·
Abeona reports $11.4 million in ZEVASKYN revenue, up 31% from prior quarter
ABEOAbeona Therapeutics Inc.
Abeona Therapeutics Inc. reported financial results for the quarter ended June 30, 2026, showing net ZEVASKYN revenue of $11.4 million, a 31% increase from the prior quarter. The company treated five patients with its gene therapy product during the period and holds $146.8 million in cash and short-term investments. Abeona also announced that CMS will grant New Technology Add-On Payment status for ZEVASKYN starting October 1, 2026, facilitating access for Medicare beneficiaries. The company operates as a commercial-stage biopharmaceutical firm developing cell and gene therapies.